

Speaking Engagements | December 3 - 4, 2025

ACI's 30th Annual Conference on Drug & Medical Device Litigation

New York Marriott Marquis
1535 Broadway
New York, New York 10036

SPEAKERS

[Halli Cohn](#)

December 3 – 4, 2025

Troutman Pepper Locke is proud to sponsor ACI's 30th Annual Conference on Drug & Medical Device Litigation, to be held on December 3-4, 2025 in New York, NY. Partner Halli Cohn will be speaking on a panel entitled, "Exit Strategies: Practical Tactics for Closing Out Complex Mass Tort Exposure," on December 4 at 12:00 PM ET.

Session Overview:

Winding down drug and device litigations is a daunting task, but no company wants to be embroiled in massive litigation long term. This session will address real world strategies for developing and implementing an effective exit strategy and identify common challenges in product liability settlements. Topics of discussion will include:

- Conducting an early assessment of risk and exposure:
 - Engaging key consulting experts early
 - Aligning exit strategy with business goals
- Developing a case management schedule to limit claims and claimants:
 - Instituting an effective and targeted motion practice
- Coordinating with parallel proceedings
- Building and maintaining working relationships among plaintiffs' leadership:
 - Looking at the pros and cons of separate settlement and litigation teams
 - Examining the role of census registry (and PFS process) in facilitating discussions
- Creative mediation and settlement strategies

The event offers a valuable chance to connect with stakeholders in product liability defense, including industry professionals, private practitioners, and members of the Bench. Over two days, attendees will engage in interactive discussions and networking to explore the current and future landscape of product liability litigation.

The program features insights from industry leaders on challenges facing the drug and medical device community, including AI-related risks in drug development and medical device usage. Topics covered include new MDL case management changes, Rule 702 amendments, bankruptcy as a mass tort resolution strategy, and litigation exit strategies.

RELATED INDUSTRIES + PRACTICES

- [Health Care + Life Sciences](#)
- [Pharmaceutical + Medical Device Litigation + Counseling](#)